Aurinia Pharmaceuticals (AUPH) Financials

$8.39 +0.80 (+10.54%)

Closing price 04:00 PM Eastern

Extended Trading

$8.29 -0.10 (-1.14%)

As of 07:56 PM Eastern

Annual Income Statements for Aurinia Pharmaceuticals

This table shows Aurinia Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-23	-71	-54	-88	-103	-181	-108	-78	5.75
Consolidated Net Income / (Loss)	-23	-71	-53	-88	-103	-181	-108	-78	5.75
Net Income / (Loss) Continuing Operations	-23	-71	-54	-88	-103	-181	-108	-78	5.75
Total Pre-Tax Income	-23	-71	-53	-88	-103	-180	-106	-77	7.45
Total Operating Income	-25	-47	-55	-91	-104	-181	-111	-92	-4.69
Total Gross Profit	0.00	0.42	0.46	0.32	50	45	128	161	207
Total Revenue	0.17	0.42	0.46	0.32	50	46	134	176	235
Operating Revenue	0.01	-	0.46	0.32	50	46	134	176	235
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	1.09	5.66	14	28
Operating Cost of Revenue	0.00	-	-	0.00	0.00	1.09	5.66	14	28
Total Operating Expenses	25	47	57	91	154	225	240	253	212
Selling, General & Admin Expense	6.97	12	14	22	97	174	196	195	172
Research & Development Expense	15	34	41	53	50	51	45	50	21
Other Operating Expenses / (Income)	2.21	-0.20	-0.67	15	6.81	0.57	-1.52	8.38	-4.35
Restructuring Charge	-	-	-	-	-	-	0.00	0.00	23
Total Other Income / (Expense), net	1.73	-24	2.23	2.70	1.52	0.53	5.12	14	12
Interest Expense	-	-	-	-	-	0.00	0.00	2.78	4.84
Interest & Investment Income	-	-	2.23	2.70	1.52	0.53	5.12	17	17
Income Tax Expense	-	-	0.07	0.14	-0.09	0.76	1.83	0.55	1.70
Basic Earnings per Share	($0.66)	($0.92)	($0.63)	($0.95)	($0.87)	($1.40)	($0.76)	($0.54)	$0.04
Weighted Average Basic Shares Outstanding	-	84.05M	84.78M	93.02M	118.47M	129.37M	141.92M	143.24M	143.06M
Diluted Earnings per Share	($0.66)	($0.92)	($0.63)	($0.95)	($0.87)	($1.40)	($0.76)	($0.54)	$0.04
Weighted Average Diluted Shares Outstanding	-	84.05M	84.78M	93.02M	118.47M	129.37M	141.92M	143.24M	146.19M
Weighted Average Basic & Diluted Shares Outstanding	-	84.05M	84.78M	93.02M	118.47M	129.37M	142.58M	144.62M	137.34M

This table shows Aurinia Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-8.99	-26	-26	-12	-13	-27	-11	0.72	15	0.96	23
Consolidated Net Income / (Loss)	-8.99	-26	-26	-11	-13	-27	-11	0.72	14	1.43	23
Net Income / (Loss) Continuing Operations	-8.99	-26	-26	-11	-13	-27	-11	0.72	14	1.43	23
Total Pre-Tax Income	-8.04	-25	-26	-12	-13	-26	-10	1.48	15	1.17	24
Total Operating Income	-9.50	-28	-30	-16	-16	-30	-13	-1.51	12	-1.67	22
Total Gross Profit	53	27	34	40	48	40	43	48	62	54	54
Total Revenue	56	28	34	41	55	45	50	57	68	60	62
Operating Revenue	56	28	34	41	55	45	50	57	68	60	62
Total Cost of Revenue	2.45	1.36	0.42	1.56	6.77	5.40	7.75	8.91	6.04	5.55	8.57
Operating Cost of Revenue	2.45	1.36	0.42	1.56	6.77	5.40	7.75	8.91	6.04	5.55	8.57
Total Operating Expenses	63	55	64	56	64	69	56	50	50	56	32
Selling, General & Admin Expense	52	47	50	47	48	50	48	45	42	37	20
Research & Development Expense	11	9.87	13	13	14	10	5.55	4.08	3.05	8.11	5.74
Other Operating Expenses / (Income)	-0.31	-2.17	0.29	-3.63	2.65	9.07	-4.13	-0.29	4.57	-4.51	4.43
Restructuring Charge	-	-	0.00	0.00	0.00	-	6.68	1.07	0.00	15	1.53
Total Other Income / (Expense), net	1.46	2.91	3.81	4.04	3.11	3.26	3.24	2.99	3.06	2.84	2.50
Interest Expense	0.00	-	0.00	0.07	1.40	1.31	1.28	1.20	1.21	1.15	1.07
Interest & Investment Income	1.46	2.91	3.81	4.10	4.51	4.57	4.53	4.19	4.27	3.99	3.57
Income Tax Expense	0.95	0.86	0.44	-0.64	0.30	0.46	0.74	0.76	0.46	-0.26	1.01
Basic Earnings per Share	($0.06)	($0.18)	($0.18)	($0.08)	($0.09)	($0.19)	($0.07)	$0.01	$0.10	-	$0.17
Weighted Average Basic Shares Outstanding	141.86M	141.92M	142.64M	142.78M	142.85M	143.24M	144.01M	143.33M	143.05M	143.06M	138.92M
Diluted Earnings per Share	($0.06)	($0.18)	($0.18)	($0.08)	($0.09)	($0.19)	($0.07)	$0.01	$0.10	-	$0.16
Weighted Average Diluted Shares Outstanding	141.86M	141.92M	142.64M	142.78M	142.85M	143.24M	144.01M	144.11M	145.65M	146.19M	143.20M
Weighted Average Basic & Diluted Shares Outstanding	142.11M	142.58M	143.03M	143.42M	143.61M	144.62M	143.02M	142.99M	143.18M	137.34M	135.10M

This table details how cash moves in and out of Aurinia Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	44	126	-48	188	-34	-40	-138	-45	35
Net Cash From Operating Activities	-21	-41	-52	-64	-70	-158	-80	-33	44
Net Cash From Continuing Operating Activities	-21	-41	-52	-64	-70	-158	-80	-33	44
Net Income / (Loss) Continuing Operations	-23	-71	-53	-88	-103	-181	-108	-78	5.75
Consolidated Net Income / (Loss)	-23	-71	-53	-88	-103	-181	-108	-78	5.75
Depreciation Expense	-	0.02	0.02	0.03	1.37	2.76	2.71	12	19
Amortization Expense	1.29	-0.12	1.29	1.14	-	0.66	-1.57	-12	-13
Non-Cash Adjustments To Reconcile Net Income	1.25	30	6.15	22	21	42	34	51	26
Changes in Operating Assets and Liabilities, net	-	-	-6.00	2.03	10	-22	-6.82	-5.61	5.45
Net Cash From Investing Activities	31	-8.00	-0.07	7.78	-158	-104	-61	-6.71	39
Net Cash From Continuing Investing Activities	31	-8.00	-0.07	7.78	-158	-104	-61	-6.71	39
Purchase of Property, Plant & Equipment	-	-0.03	-0.07	-0.09	-7.34	-1.50	-0.29	-0.72	-0.28
Purchase of Investments	-	-98	-36	0.00	-203	-445	-524	-524	-546
Sale and/or Maturity of Investments	31	90	36	7.88	52	354	464	529	585
Other Investing Activities, net	-	-	-	0.00	0.00	-12	-0.66	-12	-0.04
Net Cash From Financing Activities	34	175	4.01	244	194	221	2.43	-5.13	-49
Net Cash From Continuing Financing Activities	34	166	4.01	244	194	221	2.43	-5.13	-49
Repurchase of Common Equity	-	-	-	-	-	-	0.00	0.00	-40
Issuance of Common Equity	7.82	162	0.00	223	188	197	1.91	1.85	1.08
Other Financing Activities, net	-	4.14	4.01	21	6.64	24	0.52	-6.98	-9.94
Cash Income Taxes Paid	-	-	0.00	0.06	0.26	0.26	1.98	0.50	2.18

This table details how cash moves in and out of Aurinia Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	-66	8.12	-5.17	-7.29	-35	2.48	16	-31	3.74	46	-17
Net Cash From Operating Activities	-15	10	-32	-2.83	-13	14	-19	16	17	30	1.30
Net Cash From Continuing Operating Activities	-15	10	-32	-2.83	-13	14	-19	16	17	30	1.30
Net Income / (Loss) Continuing Operations	-8.99	-26	-26	-11	-13	-27	-11	0.72	14	1.43	23
Consolidated Net Income / (Loss)	-8.99	-26	-26	-11	-13	-27	-11	0.72	14	1.43	23
Depreciation Expense	1.11	0.22	0.72	0.72	5.26	4.95	4.85	4.84	4.89	4.86	4.86
Amortization Expense	-0.67	-1.56	-2.61	-2.99	-3.24	-3.31	-3.21	-3.13	-3.42	-2.98	-2.66
Non-Cash Adjustments To Reconcile Net Income	9.58	5.87	9.68	8.82	12	20	1.27	7.62	13	4.32	0.73
Changes in Operating Assets and Liabilities, net	-16	32	-13	2.12	-14	19	-11	5.78	-12	22	-25
Net Cash From Investing Activities	-50	-3.02	25	-5.61	-20	-6.26	49	-39	-11	39	31
Net Cash From Continuing Investing Activities	-50	-3.02	25	-5.61	-20	-6.26	49	-39	-11	39	31
Purchase of Property, Plant & Equipment	-0.04	-0.13	-0.35	-0.18	0.11	-0.30	-0.01	-	-	-0.28	-0.02
Purchase of Investments	-170	-121	-142	-114	-123	-144	-121	-197	-143	-85	-92
Sale and/or Maturity of Investments	120	118	168	121	103	138	171	158	133	124	123
Net Cash From Financing Activities	-	0.69	1.64	1.14	-2.33	-5.58	-15	-8.27	-2.72	-23	-49
Net Cash From Continuing Financing Activities	-	0.69	1.64	1.14	-2.33	-5.58	-15	-8.27	-2.72	-23	-49
Repurchase of Common Equity	-	-	0.00	-	-	-	-12	-6.13	-	-22	-47
Other Financing Activities, net	-	-1.22	1.64	1.14	-2.33	-7.43	-2.75	-2.14	-2.72	-2.33	-2.42
Cash Income Taxes Paid	-	1.20	0.00	0.28	0.06	0.16	0.00	1.46	-	0.73	0.25

This table presents Aurinia Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	57	190	146	324	464	543	471	548	551
Total Current Assets	40	175	133	315	419	513	443	425	447
Cash & Equivalents	40	166	118	306	272	232	94	49	83
Short-Term Investments	0.00	7.83	7.89	0.00	126	234	295	302	275
Accounts Receivable	0.09	0.11	0.22	0.37	0.00	15	13	24	37
Inventories, net	-	-	-	0.00	14	19	25	40	39
Prepaid Expenses	-	1.68	6.78	8.75	7.17	12	14	9.49	11
Other Current Assets	-	-	-	-	-	0.80	1.33	1.03	1.13
Plant, Property, & Equipment, net	0.00	0.03	0.04	0.09	4.79	4.42	3.65	3.35	2.73
Total Noncurrent Assets	17	15	13	9.07	39	26	25	120	101
Noncurrent Note & Lease Receivables	-	-	-	-	-	-	0.00	109	92
Intangible Assets	16	14	13	8.86	9.33	8.40	6.43	4.98	4.36
Other Noncurrent Operating Assets	1.71	0.45	0.36	0.21	5.74	17	18	6.02	4.89
Total Liabilities & Shareholders' Equity	57	190	146	324	464	543	471	548	551
Total Liabilities	21	24	33	26	56	64	65	170	173
Total Current Liabilities	5.79	8.15	7.26	11	32	41	46	77	98
Accounts Payable	5.79	7.96	7.07	11	25	35	40	4.33	5.19
Accrued Expenses	-	-	-	-	-	-	-	50	65
Current Deferred Revenue	-	0.12	0.12	-	-	0.19	3.15	4.81	11
Other Current Liabilities	-	-	-	0.12	7.20	5.51	2.97	18	17
Total Noncurrent Liabilities	50	12	22	14	24	24	19	93	75
Noncurrent Deferred Revenue	0.68	0.44	0.32	-	-	-	-	-	1.70
Other Noncurrent Operating Liabilities	50	-	-	14	24	24	19	93	74
Commitments & Contingencies	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	0.97	166	113	299	408	479	405	378	377
Total Preferred & Common Equity	0.97	166	113	299	408	479	405	378	377
Total Common Equity	0.97	166	113	299	408	479	405	378	377
Common Stock	-	499	505	772	984	1,236	1,271	1,321	1,315
Retained Earnings	-	-352	-416	-472	-575	-756	-864	-942	-937
Accumulated Other Comprehensive Income / (Loss)	-	-0.88	-0.81	-0.81	-0.81	-0.85	-1.06	-0.73	-0.65

This table presents Aurinia Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	6/30/2022	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025
Total Assets	482	488	452	549	555	517	524	549	505
Total Current Assets	453	460	424	416	426	398	410	440	406
Cash & Equivalents	152	86	89	82	46	64	33	37	66
Short-Term Investments	240	291	273	269	292	255	297	312	246
Accounts Receivable	18	42	19	19	38	29	26	36	40
Inventories, net	26	25	32	33	33	40	39	39	46
Prepaid Expenses	17	12	10	11	16	7.65	7.84	14	5.54
Other Current Assets	-	3.81	1.23	1.21	1.65	2.00	6.98	2.70	0.78
Plant, Property, & Equipment, net	4.18	3.76	3.84	3.65	3.50	3.20	3.04	2.89	2.58
Total Noncurrent Assets	25	25	24	129	125	115	111	106	97
Noncurrent Note & Lease Receivables	-	-	-	117	113	104	101	-	88
Intangible Assets	7.34	6.84	6.10	5.68	5.26	4.76	4.62	4.51	4.16
Other Noncurrent Operating Assets	17	18	18	6.23	6.13	5.90	5.16	102	4.78
Total Liabilities & Shareholders' Equity	482	488	452	549	555	517	524	549	505
Total Liabilities	58	65	61	157	163	157	159	161	155
Total Current Liabilities	35	42	42	62	74	71	77	79	68
Accounts Payable	32	40	36	41	52	50	56	57	4.22
Accrued Expenses	-	-	-	-	-	-	-	-	42
Current Deferred Revenue	-	-	3.16	3.23	4.66	4.91	4.37	4.30	4.59
Other Current Liabilities	2.25	1.64	2.92	17	17	16	16	18	17
Total Noncurrent Liabilities	24	23	19	95	89	86	82	83	86
Noncurrent Deferred Revenue	-	-	-	-	-	-	-	-	12
Other Noncurrent Operating Liabilities	24	23	19	95	89	86	82	83	74
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	424	423	390	392	392	359	365	388	350
Total Preferred & Common Equity	424	423	390	392	392	359	365	388	350
Total Common Equity	424	423	390	392	392	359	365	388	350
Common Stock	1,255	1,263	1,282	1,295	1,308	1,313	1,318	1,326	1,264
Retained Earnings	-829	-838	-891	-902	-915	-953	-952	-938	-913
Accumulated Other Comprehensive Income / (Loss)	-1.85	-1.53	-0.99	-1.02	-0.95	-0.85	-0.86	-0.39	-0.83

This table displays calculated financial ratios and metrics derived from Aurinia Pharmaceuticals' official financial filings.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	141.62%	10.77%	-31.32%	15,660.38%	-9.00%	193.89%	30.95%	33.97%
EBITDA Growth	0.00%	-222.13%	23.93%	-66.47%	-14.64%	-72.29%	37.77%	16.45%	102.20%
EBIT Growth	0.00%	-203.89%	21.97%	-64.63%	-14.68%	-73.30%	38.32%	17.74%	94.89%
NOPAT Growth	0.00%	-87.27%	-17.86%	-64.63%	-14.68%	-73.30%	38.32%	17.74%	94.36%
Net Income Growth	0.00%	-203.89%	25.02%	-66.52%	-16.17%	-76.24%	40.22%	27.88%	107.37%
EPS Growth	0.00%	-39.39%	31.52%	-50.79%	8.42%	-60.92%	45.71%	28.95%	107.41%
Operating Cash Flow Growth	0.00%	-98.33%	-25.36%	-23.20%	-9.87%	-125.73%	49.57%	57.93%	232.66%
Free Cash Flow Firm Growth	0.00%	0.00%	45.44%	-1.04%	-49.64%	-135.99%	47.53%	6.98%	106.16%
Invested Capital Growth	0.00%	120.34%	58.84%	-159.38%	-101.63%	186.99%	23.30%	69.92%	-30.30%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-36.86%	3.90%	10.49%	6.70%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-16.09%	2.23%	1.51%	107.73%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-15.79%	3.97%	-1.75%	85.66%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-15.79%	3.97%	-1.75%	84.18%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-16.21%	6.30%	-1.07%	125.51%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-14.75%	7.32%	-1.89%	126.67%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-22.65%	31.38%	10.35%	55.28%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	30.28%	-8.20%	153.03%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	10.54%	-65.70%	-48.93%	-51.59%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	0.58%	100.00%	100.00%	100.00%	100.00%	97.61%	95.77%	91.94%	87.99%
EBITDA Margin	-12,720.23%	-16,958.85%	-11,647.30%	-28,230.19%	-205.35%	-388.80%	-82.32%	-52.52%	0.86%
Operating Margin	-14,466.47%	-11,212.44%	-11,930.89%	-28,598.43%	-208.09%	-396.31%	-83.17%	-52.24%	-1.99%
EBIT Margin	-13,465.32%	-16,935.89%	-11,930.89%	-28,598.43%	-208.09%	-396.31%	-83.17%	-52.24%	-1.99%
Profit (Net Income) Margin	-13,465.32%	-16,935.89%	-11,464.15%	-27,794.03%	-204.88%	-396.81%	-80.71%	-44.45%	2.45%
Tax Burden Percent	100.00%	100.00%	100.14%	100.16%	99.91%	100.42%	101.72%	100.71%	77.23%
Interest Burden Percent	100.00%	100.00%	95.96%	97.03%	98.55%	99.71%	95.41%	84.49%	-158.91%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	22.77%
Return on Invested Capital (ROIC)	0.00%	0.00%	-379.84%	-2,508.77%	0.00%	0.00%	-537.06%	-296.40%	-15.65%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-368.67%	-2,496.60%	0.00%	0.00%	-530.01%	-292.66%	-18.29%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	341.70%	2,465.78%	0.00%	0.00%	512.60%	276.48%	17.17%
Return on Equity (ROE)	-2,399.07%	-84.93%	-38.14%	-42.99%	-29.07%	-40.81%	-24.46%	-19.92%	1.52%
Cash Return on Invested Capital (CROIC)	0.00%	-1,008.79%	-425.30%	0.00%	0.00%	-1,187.17%	-557.93%	-348.21%	20.07%
Operating Return on Assets (OROA)	-40.87%	-57.36%	-32.91%	-38.69%	-26.47%	-35.89%	-21.98%	-18.00%	-0.85%
Return on Assets (ROA)	-40.87%	-57.36%	-31.62%	-37.60%	-26.06%	-35.94%	-21.33%	-15.31%	1.05%
Return on Common Equity (ROCE)	-2,399.07%	-84.93%	-38.14%	-42.99%	-29.07%	-40.81%	-24.46%	-19.92%	1.52%
Return on Equity Simple (ROE_SIMPLE)	-2,399.07%	-42.71%	-47.15%	-29.60%	-25.18%	-37.77%	-26.68%	-20.64%	1.52%
Net Operating Profit after Tax (NOPAT)	-18	-33	-39	-64	-73	-127	-78	-64	-3.62
NOPAT Margin	-10,126.53%	-7,848.71%	-8,351.62%	-20,018.90%	-145.66%	-277.41%	-58.22%	-36.57%	-1.54%
Net Nonoperating Expense Percent (NNEP)	-14.57%	-38.46%	-11.17%	-12.18%	-8.14%	-12.25%	-7.05%	-3.74%	2.64%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-19.25%	-16.98%	-0.96%
Cost of Revenue to Revenue	2.31%	0.00%	0.00%	0.00%	0.00%	2.39%	4.23%	8.06%	12.01%
SG&A Expenses to Revenue	4,028.90%	2,893.78%	2,957.67%	7,024.53%	194.09%	380.52%	146.51%	111.12%	73.16%
R&D to Revenue	8,401.16%	8,117.22%	8,937.80%	16,624.53%	100.42%	112.13%	33.57%	28.28%	8.84%
Operating Expenses to Revenue	14,564.16%	11,312.44%	12,318.57%	28,698.43%	308.09%	493.91%	178.94%	144.18%	89.98%
Earnings before Interest and Taxes (EBIT)	-23	-71	-55	-91	-104	-181	-111	-92	-4.69
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-22	-71	-54	-90	-103	-177	-110	-92	2.03
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	5.09	5.80	3.79	6.19	1.51	3.42	3.41
Price to Tangible Book Value (P/TBV)	0.00	0.00	5.73	5.98	3.88	6.30	1.54	3.46	3.45
Price to Revenue (P/Rev)	0.00	0.00	1,238.08	5,447.28	30.85	65.03	4.58	7.36	5.47
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	223.53
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.45%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	37.55	0.00	0.00	192.08	13.99	34.49	48.80
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	1,013.23	4,484.95	22.42	54.81	1.68	5.36	3.94
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	457.46
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	20.89
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	199.75
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.07	0.19	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.07	0.19	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-40.83	-1.18	-0.93	-0.99	-1.03	-1.00	-0.97	-0.94	-0.94
Leverage Ratio	58.70	1.48	1.21	1.14	1.12	1.14	1.15	1.30	1.45
Compound Leverage Factor	58.70	1.48	1.16	1.11	1.10	1.13	1.09	1.10	-2.31
Debt to Total Capital	0.00%	6.64%	16.19%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	6.64%	16.19%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	93.36%	83.81%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	-0.17	-0.40	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	2.28	1.93	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	-0.17	-0.40	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	-0.36	-0.56	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	4.93	2.69	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	-0.36	-0.56	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	0.00	6.13	38.60	15.22	25.76	3.57	2.68	3.23
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	6.86	21.50	18.30	27.90	13.11	12.63	9.60	5.50	4.57
Quick Ratio	6.86	21.30	17.36	27.13	12.45	11.85	8.74	4.85	4.04
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-79	-43	-44	-65	-154	-81	-75	4.64
Operating Cash Flow to CapEx	0.00%	-164,676.00%	-69,744.59%	-74,805.88%	-951.36%	-10,505.80%	-27,235.96%	-4,660.31%	15,796.44%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-27.17	0.96
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-12.06	9.18
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-12.32	9.12
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.13	0.09	0.26	0.34	0.43
Accounts Receivable Turnover	2.01	4.29	2.84	1.09	0.00	0.00	9.28	9.34	7.76
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.07	0.26	0.44	0.72
Fixed Asset Turnover	0.00	0.00	12.86	4.75	20.54	9.91	33.23	50.12	77.28
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.04	0.15	0.64	5.94
Days Sales Outstanding (DSO)	181.45	85.14	128.50	335.73	0.00	0.00	39.35	39.07	47.06
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	5,562.49	1,420.24	831.45	509.96
Days Payable Outstanding (DPO)	528,428.75	0.00	0.00	0.00	0.00	9,993.84	2,414.55	571.66	61.47
Cash Conversion Cycle (CCC)	-528,247.30	85.14	128.50	335.73	0.00	-4,431.35	-954.96	298.86	495.55
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	-39	7.87	12	-7.42	-15	13	16	27	19
Invested Capital Turnover	0.00	-0.03	0.05	0.13	-4.48	-46.87	9.23	8.11	10.16
Increase / (Decrease) in Invested Capital	0.00	47	4.63	-20	-7.54	28	3.03	11	-8.26
Enterprise Value (EV)	0.00	0.00	469	1,426	1,123	2,499	225	940	927
Market Capitalization	0.00	0.00	573	1,732	1,546	2,966	614	1,291	1,286
Book Value per Share	$0.00	$1.97	$1.34	$3.49	$3.65	$3.69	$2.85	$2.63	$2.64
Tangible Book Value per Share	$0.00	$1.80	$1.19	$3.39	$3.56	$3.63	$2.81	$2.60	$2.61
Total Capital	0.97	178	134	299	408	479	405	378	377
Total Debt	0.00	12	22	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	12	22	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-40	-162	-104	-306	-423	-466	-389	-351	-358
Capital Expenditures (CapEx)	-0.02	0.03	0.07	0.09	7.34	1.50	0.29	0.72	0.28
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-5.71	-6.36	-0.27	-2.18	-11	6.60	7.04	-2.88	-9.64
Debt-free Net Working Capital (DFNWC)	34	167	126	304	387	473	396	348	349
Net Working Capital (NWC)	34	167	126	304	387	473	396	348	349
Net Nonoperating Expense (NNE)	5.78	38	14	25	30	54	30	14	-9.37
Net Nonoperating Obligations (NNO)	-40	-158	-100	-306	-423	-466	-389	-351	-358
Total Depreciation and Amortization (D&A)	1.29	-0.10	1.31	1.17	1.37	3.42	1.13	-0.49	6.71
Debt-free, Cash-free Net Working Capital to Revenue	-3,297.69%	-1,521.53%	-58.10%	-684.59%	-21.75%	14.47%	5.25%	-1.64%	-4.10%
Debt-free Net Working Capital to Revenue	19,620.81%	39,976.56%	27,124.62%	95,547.80%	773.04%	1,036.46%	295.78%	198.05%	148.36%
Net Working Capital to Revenue	19,620.81%	39,976.56%	27,124.62%	95,547.80%	773.04%	1,036.46%	295.78%	198.05%	148.36%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($0.92)	($0.76)	$0.00	($0.87)	($1.40)	($0.76)	($0.54)	$0.04
Adjusted Weighted Average Basic Shares Outstanding	0.00	84.05M	85.50M	111.80M	127.45M	141.65M	141.92M	143.24M	143.06M
Adjusted Diluted Earnings per Share	$0.00	($0.92)	($0.76)	$0.00	($0.87)	($1.40)	($0.76)	($0.54)	$0.04
Adjusted Weighted Average Diluted Shares Outstanding	0.00	84.05M	85.50M	111.80M	127.45M	141.65M	141.92M	143.24M	146.19M
Adjusted Basic & Diluted Earnings per Share	$0.00	($0.92)	($0.76)	$0.00	($0.87)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	84.05M	85.50M	111.80M	118.47M	129.37M	142.58M	144.62M	137.34M
Normalized Net Operating Profit after Tax (NOPAT)	-18	-33	-39	-64	-73	-127	-78	-64	14
Normalized NOPAT Margin	-10,126.53%	-7,848.71%	-8,351.62%	-20,018.90%	-145.66%	-277.41%	-58.22%	-36.57%	6.05%
Pre Tax Income Margin	-13,465.32%	-16,935.89%	-11,448.38%	-27,748.74%	-205.06%	-395.15%	-79.35%	-44.14%	3.17%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-33.04	-0.97
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-23.13	-0.75
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-33.30	-1.03
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-23.39	-0.81
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	699.57%

This table displays calculated financial ratios and metrics derived from Aurinia Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	280.30%	21.50%	59.12%	47.19%	-2.27%	58.59%	46.19%	37.83%	24.32%	32.76%	24.18%
EBITDA Growth	81.74%	7.93%	14.70%	47.22%	-57.24%	4.79%	63.11%	101.11%	192.85%	100.76%	307.09%
EBIT Growth	81.14%	14.08%	21.90%	55.07%	-71.21%	-5.60%	55.20%	90.64%	172.24%	94.38%	264.85%
NOPAT Growth	81.14%	14.08%	21.90%	55.07%	-71.21%	-5.60%	55.20%	93.47%	200.01%	90.21%	325.77%
Net Income Growth	82.11%	21.84%	30.36%	67.64%	-49.59%	-3.18%	58.98%	106.28%	206.72%	105.32%	317.17%
EPS Growth	84.62%	25.00%	33.33%	68.00%	-50.00%	-5.56%	61.11%	112.50%	211.11%	0.00%	328.57%
Operating Cash Flow Growth	61.83%	140.31%	32.25%	89.86%	13.57%	36.96%	41.28%	660.62%	228.26%	110.41%	106.99%
Free Cash Flow Firm Growth	11.40%	55.37%	56.55%	57.16%	56.82%	-40.92%	2.20%	133.06%	241.84%	119.47%	216.46%
Invested Capital Growth	297.39%	23.30%	-1.69%	29.80%	14.12%	69.92%	36.33%	-18.37%	-26.47%	-30.30%	-5.27%
Revenue Q/Q Growth	97.86%	-49.02%	21.01%	20.59%	31.38%	-17.28%	11.55%	13.70%	18.50%	-11.66%	4.34%
EBITDA Q/Q Growth	74.08%	-225.11%	-6.93%	41.42%	22.78%	-96.87%	58.57%	101.77%	6,348.78%	-98.38%	11,136.92%
EBIT Q/Q Growth	73.61%	-195.82%	-5.28%	45.34%	-0.58%	-82.46%	55.34%	88.58%	876.47%	-114.21%	1,408.99%
NOPAT Q/Q Growth	73.61%	-195.82%	-5.28%	45.34%	-0.58%	-82.46%	55.34%	92.03%	1,640.45%	-117.86%	1,130.14%
Net Income Q/Q Growth	74.69%	-189.75%	-0.61%	56.15%	-17.01%	-99.86%	60.00%	106.72%	1,887.53%	-90.04%	1,533.59%
EPS Q/Q Growth	76.00%	-200.00%	0.00%	55.56%	-12.50%	-111.11%	63.16%	114.29%	900.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	44.88%	168.03%	-403.06%	91.08%	-369.82%	207.80%	-229.95%	185.19%	7.49%	76.84%	-95.68%
Free Cash Flow Firm Q/Q Growth	14.47%	45.50%	10.97%	-3.24%	13.79%	-77.83%	38.21%	134.89%	269.92%	-75.59%	269.60%
Invested Capital Q/Q Growth	46.04%	-65.70%	79.96%	44.00%	28.40%	-48.93%	44.38%	-13.78%	15.65%	-51.59%	96.24%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	95.61%	95.21%	98.78%	96.23%	87.58%	88.04%	84.59%	84.42%	91.10%	90.73%	86.27%
EBITDA Margin	-16.23%	-103.53%	-91.48%	-44.44%	-26.12%	-62.16%	-23.08%	0.36%	19.51%	0.36%	38.50%
Operating Margin	-17.03%	-98.82%	-85.98%	-38.97%	-29.83%	-65.80%	-26.35%	-2.65%	17.33%	-2.79%	34.97%
EBIT Margin	-17.03%	-98.82%	-85.98%	-38.97%	-29.83%	-65.80%	-26.35%	-2.65%	17.33%	-2.79%	34.97%
Profit (Net Income) Margin	-16.12%	-91.60%	-76.16%	-27.70%	-24.67%	-59.60%	-21.37%	1.26%	21.17%	2.39%	37.37%
Tax Burden Percent	111.87%	103.39%	101.69%	94.71%	102.27%	101.74%	107.38%	48.85%	96.91%	121.82%	95.87%
Interest Burden Percent	84.59%	89.65%	87.11%	75.04%	80.85%	89.02%	75.53%	-97.69%	126.04%	-70.28%	111.45%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	51.15%	3.09%	-21.82%	4.13%
Return on Invested Capital (ROIC)	-52.53%	-638.14%	-303.40%	-118.67%	-66.23%	-373.34%	-103.46%	-7.09%	79.92%	-34.52%	216.35%
ROIC Less NNEP Spread (ROIC-NNEP)	-51.82%	-636.65%	-302.00%	-118.63%	-65.66%	-371.69%	-103.03%	-7.52%	79.06%	-35.50%	215.59%
Return on Net Nonoperating Assets (RNNOA)	47.62%	615.74%	281.02%	107.92%	57.59%	351.14%	93.65%	6.77%	-69.67%	33.32%	-192.31%
Return on Equity (ROE)	-4.91%	-22.41%	-22.39%	-10.75%	-8.64%	-22.20%	-9.81%	-0.32%	10.25%	-1.20%	24.05%
Cash Return on Invested Capital (CROIC)	-397.12%	-557.93%	-246.28%	-184.47%	-139.14%	-348.21%	-185.36%	-92.31%	-18.90%	20.07%	81.04%
Operating Return on Assets (OROA)	-5.18%	-26.12%	-26.33%	-12.10%	-9.08%	-22.67%	-10.41%	-1.02%	6.92%	-1.19%	16.93%
Return on Assets (ROA)	-4.90%	-24.21%	-23.33%	-8.60%	-7.51%	-20.53%	-8.45%	0.49%	8.45%	1.02%	18.09%
Return on Common Equity (ROCE)	-4.91%	-22.41%	-22.39%	-10.75%	-8.64%	-22.20%	-9.81%	-0.32%	10.25%	-1.20%	24.05%
Return on Equity Simple (ROE_SIMPLE)	-27.27%	0.00%	-24.78%	-18.54%	-19.70%	0.00%	-17.40%	-13.81%	-5.81%	0.00%	11.38%
Net Operating Profit after Tax (NOPAT)	-6.65	-20	-21	-11	-11	-21	-9.28	-0.74	11	-2.03	21
NOPAT Margin	-11.92%	-69.18%	-60.18%	-27.28%	-20.88%	-46.06%	-18.44%	-1.29%	16.80%	-3.40%	33.53%
Net Nonoperating Expense Percent (NNEP)	-0.71%	-1.49%	-1.41%	-0.05%	-0.58%	-1.65%	-0.43%	0.43%	0.86%	0.98%	0.76%
Return On Investment Capital (ROIC_SIMPLE)	-	-4.85%	-	-	-	-5.50%	-	-	-	-0.54%	5.98%
Cost of Revenue to Revenue	4.39%	4.79%	1.22%	3.77%	12.42%	11.96%	15.41%	15.58%	8.91%	9.27%	13.73%
SG&A Expenses to Revenue	93.53%	166.95%	145.67%	113.46%	87.61%	111.04%	94.82%	78.57%	62.51%	61.86%	32.56%
R&D to Revenue	19.67%	34.71%	38.24%	30.49%	24.96%	22.68%	11.04%	7.13%	4.50%	13.54%	9.19%
Operating Expenses to Revenue	112.64%	194.03%	184.75%	135.20%	117.42%	153.84%	110.94%	87.07%	73.76%	93.51%	51.30%
Earnings before Interest and Taxes (EBIT)	-9.50	-28	-30	-16	-16	-30	-13	-1.51	12	-1.67	22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-9.06	-29	-31	-18	-14	-28	-12	0.21	13	0.21	24
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.52	1.51	4.00	3.53	2.84	3.42	2.00	2.24	2.70	3.41	3.15
Price to Tangible Book Value (P/TBV)	2.56	1.54	4.07	3.58	2.88	3.46	2.03	2.27	2.73	3.45	3.19
Price to Revenue (P/Rev)	8.27	4.58	10.64	8.65	7.02	7.36	3.76	3.94	4.76	5.47	4.47
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	223.53	27.71
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.45%	3.61%
Enterprise Value to Invested Capital (EV/IC)	14.76	13.99	41.60	24.86	14.53	34.49	10.15	14.32	17.82	48.80	21.22
Enterprise Value to Revenue (EV/Rev)	5.35	1.68	8.18	6.46	4.88	5.36	2.09	2.35	3.17	3.94	3.20
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	457.46	21.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	26.02
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	27.30
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	24.47	20.89	12.31
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	199.75	25.48
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.92	-0.97	-0.93	-0.91	-0.88	-0.94	-0.91	-0.90	-0.88	-0.94	-0.89
Leverage Ratio	1.18	1.15	1.14	1.26	1.28	1.30	1.29	1.42	1.42	1.45	1.44
Compound Leverage Factor	0.99	1.03	1.00	0.95	1.03	1.16	0.98	-1.38	1.78	-1.02	1.60
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	8.69	4.16	13.64	3.97	2.74	3.05	1.21	1.69	2.77	3.25	3.19
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	11.01	9.60	10.08	6.75	5.77	5.50	5.60	5.33	5.60	4.57	5.93
Quick Ratio	10.02	8.74	9.05	6.00	5.09	4.85	4.91	4.63	4.90	4.04	5.16
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-42	-23	-20	-21	-18	-32	-20	6.90	26	6.23	23
Operating Cash Flow to CapEx	-38,405.00%	7,798.51%	-9,126.80%	-1,596.61%	0.00%	4,786.62%	0.00%	0.00%	0.00%	10,716.73%	7,647.06%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	-321.02	-12.85	-24.42	-15.41	5.76	21.12	5.44	21.58
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	-43.48	-9.48	10.93	-14.50	13.22	14.10	26.28	1.22
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	-46.20	-9.41	10.70	-14.50	13.22	14.10	26.03	1.20
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.30	0.26	0.31	0.31	0.30	0.34	0.40	0.39	0.40	0.43	0.48
Accounts Receivable Turnover	5.00	9.28	7.44	8.50	3.99	9.34	7.98	9.20	5.92	7.76	7.14
Inventory Turnover	0.21	0.26	0.20	0.20	0.35	0.44	0.60	0.80	0.79	0.72	0.68
Fixed Asset Turnover	31.05	33.23	35.92	40.88	43.80	50.12	54.38	61.89	69.05	77.28	85.66
Accounts Payable Turnover	0.14	0.15	0.17	0.16	0.22	0.64	0.50	0.59	0.52	5.94	1.07
Days Sales Outstanding (DSO)	72.98	39.35	49.04	42.94	91.58	39.07	45.72	39.67	61.64	47.06	51.11
Days Inventory Outstanding (DIO)	1,702.25	1,420.24	1,816.26	1,859.28	1,048.99	831.45	607.56	455.90	464.74	509.96	539.63
Days Payable Outstanding (DPO)	2,674.47	2,414.55	2,138.15	2,323.54	1,667.71	571.66	732.71	619.42	708.66	61.47	342.09
Cash Conversion Cycle (CCC)	-899.23	-954.96	-272.85	-421.33	-527.13	298.86	-79.42	-123.85	-182.28	495.55	248.65
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	47	16	29	42	53	27	39	34	39	19	37
Invested Capital Turnover	4.41	9.23	5.04	4.35	3.17	8.11	5.61	5.48	4.76	10.16	6.45
Increase / (Decrease) in Invested Capital	35	3.03	-0.50	9.55	6.61	11	10	-7.64	-14	-8.26	-2.08
Enterprise Value (EV)	690	225	1,201	1,034	776	940	399	486	699	927	791
Market Capitalization	1,067	614	1,563	1,385	1,114	1,291	719	817	1,048	1,286	1,104
Book Value per Share	$2.98	$2.85	$2.74	$2.74	$2.73	$2.63	$2.50	$2.55	$2.71	$2.64	$2.55
Tangible Book Value per Share	$2.94	$2.81	$2.70	$2.70	$2.70	$2.60	$2.46	$2.52	$2.68	$2.61	$2.52
Total Capital	423	405	390	392	392	378	359	365	388	377	350
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-377	-389	-362	-351	-338	-351	-320	-331	-349	-358	-313
Capital Expenditures (CapEx)	0.04	0.13	0.35	0.18	-0.11	0.30	0.00	0.00	0.00	0.28	0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)	41	7.04	20	3.53	15	-2.88	7.26	2.29	13	-9.64	24
Debt-free Net Working Capital (DFNWC)	418	396	382	354	353	348	327	333	362	349	337
Net Working Capital (NWC)	418	396	382	354	353	348	327	333	362	349	337
Net Nonoperating Expense (NNE)	2.34	6.38	5.50	0.17	2.06	6.10	1.47	-1.46	-2.96	-3.46	-2.40
Net Nonoperating Obligations (NNO)	-377	-389	-362	-351	-338	-351	-320	-331	-349	-358	-313
Total Depreciation and Amortization (D&A)	0.44	-1.34	-1.89	-2.27	2.03	1.64	1.64	1.72	1.47	1.88	2.20
Debt-free, Cash-free Net Working Capital to Revenue	32.01%	5.25%	13.67%	2.21%	9.24%	-1.64%	3.79%	1.10%	5.95%	-4.10%	9.89%
Debt-free Net Working Capital to Revenue	323.98%	295.78%	259.92%	221.24%	221.95%	198.05%	170.93%	160.67%	164.21%	148.36%	136.42%
Net Working Capital to Revenue	323.98%	295.78%	259.92%	221.24%	221.95%	198.05%	170.93%	160.67%	164.21%	148.36%	136.42%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.06)	($0.18)	($0.18)	($0.08)	($0.09)	($0.19)	($0.07)	$0.01	$0.10	$0.00	$0.17
Adjusted Weighted Average Basic Shares Outstanding	141.86M	141.92M	142.64M	142.78M	142.85M	143.24M	144.01M	143.33M	143.05M	143.06M	138.92M
Adjusted Diluted Earnings per Share	($0.06)	($0.18)	($0.18)	($0.08)	($0.09)	($0.19)	($0.07)	$0.01	$0.10	$0.00	$0.16
Adjusted Weighted Average Diluted Shares Outstanding	141.86M	141.92M	142.64M	142.78M	142.85M	143.24M	144.01M	144.11M	145.65M	146.19M	143.20M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	142.11M	142.58M	143.03M	143.42M	143.61M	144.62M	143.02M	142.99M	143.18M	137.34M	135.10M
Normalized Net Operating Profit after Tax (NOPAT)	-6.65	-20	-21	-11	-11	-21	-4.60	-0.31	11	9.58	22
Normalized NOPAT Margin	-11.92%	-69.18%	-60.18%	-27.28%	-20.88%	-46.06%	-9.14%	-0.54%	16.80%	16.00%	35.88%
Pre Tax Income Margin	-14.41%	-88.59%	-74.89%	-29.24%	-24.12%	-58.58%	-19.90%	2.58%	21.85%	1.96%	38.98%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	-248.77	-11.62	-22.65	-10.33	-1.26	9.73	-1.46	20.48
NOPAT to Interest Expense	0.00	0.00	0.00	-174.14	-8.13	-15.86	-7.23	-0.62	9.43	-1.77	19.63
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	-251.49	-11.54	-22.88	-10.33	-1.26	9.73	-1.70	20.46
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	-176.86	-8.06	-16.08	-7.23	-0.62	9.43	-2.02	19.61
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	699.57%	187.88%

Key Financial Trends

Aurinia Pharmaceuticals delivered strong Q1 2025 results, with robust revenue growth, improved profitability and cash generation, while maintaining a debt-free balance sheet. At the same time, elevated working capital and rich valuation multiples warrant a closer look.

Revenue rose 24.2% year-over-year in Q1 2025 to $62.5 million, marking continued top-line momentum.
Net income jumped to $23.3 million in Q1 2025, versus $1.43 million in Q4 2024, driven by stronger operating leverage.
EBITDA improved sharply to $24.0 million in Q1 2025 from just $0.2 million in Q4 2024.
Free cash flow to the firm reached $23.0 million in Q1 2025, up from $6.2 million in the prior quarter.
The company carries no debt and ends Q1 2025 with a net cash position of $312.9 million.
Research & development spending remained at 9.2% of revenue, in line with biotech norms.
NOPAT margin for Q1 2025 stood at 33.5%, reflecting improved operational efficiency.
Days inventory outstanding reached 539 days and the cash conversion cycle was 248 days, indicating working capital inefficiencies.
Valuation appears rich with a price-to-revenue ratio of 4.47× and EV/EBITDA of 21.0×, leaving limited margin for error.
SG&A expenses remained elevated at 32.6% of revenue, continuing to pressure margins.

07/09/25 10:45 PMAI Generated. May Contain Errors.

Frequently Asked Questions About Aurinia Pharmaceuticals' Financials

When does Aurinia Pharmaceuticals' financial year end?

According to the most recent income statement we have on file, Aurinia Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Aurinia Pharmaceuticals' net income changed over the last 8 years?

Aurinia Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of $5.75 million in 2024, falling from -$23.30 million in 2016. The previous period was -$78.02 million in 2023. See where experts think Aurinia Pharmaceuticals is headed by visiting Aurinia Pharmaceuticals' forecast page.

What is Aurinia Pharmaceuticals' operating income?

Aurinia Pharmaceuticals' total operating income in 2024 was -$4.69 million, based on the following breakdown:

Total Gross Profit: $206.89 million
Total Operating Expenses: $211.57 million

How has Aurinia Pharmaceuticals' revenue changed over the last 8 years?

Over the last 8 years, Aurinia Pharmaceuticals' total revenue changed from $173 thousand in 2016 to $235.13 million in 2024, a change of 135,815.0%.

How much debt does Aurinia Pharmaceuticals have?

Aurinia Pharmaceuticals' total liabilities were at $173.17 million at the end of 2024, a 1.8% increase from 2023, and a 722.8% increase since 2016.

How much cash does Aurinia Pharmaceuticals have?

In the past 8 years, Aurinia Pharmaceuticals' cash and equivalents has ranged from $39.65 million in 2016 to $306.02 million in 2019, and is currently $83.43 million as of their latest financial filing in 2024.

How has Aurinia Pharmaceuticals' book value per share changed over the last 8 years?

Over the last 8 years, Aurinia Pharmaceuticals' book value per share changed from 0.00 in 2016 to 2.64 in 2024, a change of 263.6%.

Related Companies

This page (NASDAQ:AUPH) was last updated on 7/9/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aurinia Pharmaceuticals (AUPH) Financials

Key Financial Trends

Frequently Asked Questions About Aurinia Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aurinia Pharmaceuticals (AUPH) Financials

Annual Income Statements for Aurinia Pharmaceuticals

Quarterly Income Statements for Aurinia Pharmaceuticals

Annual Cash Flow Statements for Aurinia Pharmaceuticals

Quarterly Cash Flow Statements for Aurinia Pharmaceuticals

Annual Balance Sheets for Aurinia Pharmaceuticals

Quarterly Balance Sheets for Aurinia Pharmaceuticals

Annual Metrics And Ratios for Aurinia Pharmaceuticals

Quarterly Metrics And Ratios for Aurinia Pharmaceuticals

Key Financial Trends

Frequently Asked Questions About Aurinia Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools